Atay Oguzhan sold $4.5M of BLLN

Atay Oguzhan (Chairman and CEO) sold 32,500 shares of BillionToOne, Inc. (BLLN) at an average of $136.95 ($133.00–$139.21, $4.45M total) across 21 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Aug 6, 2026, 12:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed event is an insider open-market sale by the CEO/Chairman, executed under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst (no guidance, trial, contract, or regulatory action).

03

What to watch

The article does not indicate whether other insiders or the company also made concurrent purchases, nor does it provide context on total insider holdings beyond the post-transaction zero shares.

Relevance 5/10Novelty 3/10Timing: filed Aug 5, transaction dated Aug 3

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CEO/Chairman Atay Oguzhan filed a Form 4 selling about 32,500 shares for roughly $4.45M at $133.00 to $139.21.

Expected impact

Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed sale (not a purchase), explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating or financial guidance.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None.

None.

Counterpoint

Even with a 10b5-1 plan, large insider sales can coincide with periods of reduced confidence or liquidity needs, so some traders may still fade rallies.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Atay Oguzhan

    Chairman and CEO who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.